| Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Canadian Orthopedic Perioperative Erythropoietin Study Group. | |
| | |
MedLine Citation:
|
PMID: 8098389 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Concern about the risk of transmission of viral infection has led to attempts to reduce transfusion requirements in patients undergoing surgery. To determine whether recombinant human erythropoietin decreases blood transfusion requirements in patients undergoing elective hip arthroplasty, a multicentre double-blind, randomised, placebo-controlled trial was conducted. 208 patients undergoing elective primary or revision hip arthroplasty were randomised to 3 groups. All received daily subcutaneous injections of either erythropoietin or placebo starting 10 days before surgery. Group 1 (78 patients) received 14 days of placebo, group 2 (77 patients) received 14 days of erythropoietin (300 units/kg to a maximum of 30,000 units), and group 3 (53 patients) received placebo for days 10 to 6 before surgery and erythropoietin for the next 9 days. A primary outcome event (any transfusion or a haemoglobin concentration < 80 g/L) occurred in 46% of patients in group 1, 23% in group 2, and 32% in group 3 (p = 0.003). The mean number of transfusions was 1.14 in group 1, 0.52 in group 2, 0.70 in group 3. The mean reticulocyte count the day before surgery was 72 x 10(9)/L in group 1, 327 in group 2, and 170 in group 3. Deep venous thrombi were detected in 5 patients in group 1, 8 patients in group 2, and 8 patients in group 3. Patients who had a haemoglobin concentration before randomisation of < 135 g/L benefited most from erythropoietin. Thus erythropoietin given for 14 days perioperatively decreases the need for transfusion in patients undergoing elective hip arthroplasty. |
| | |
Authors:
|
- |
Related Documents
:
|
10735779 - Does intraoperative hetastarch administration increase blood loss and transfusion requi... 10531149 - Complement activation in coronary artery bypass grafting patients without cardiopulmona... 367709 - Comparison of hemodynamic, pulmonary, and renal effects of use of three types of fluids... 20615159 - Insulin sensitivity and related cytokines, chemokines, and adipokines in polymyalgia rh... 19204509 - Hboc-201 vasoactivity in a phase iii clinical trial in orthopedic surgery subjects--ext... 16438759 - Effect of topical tranexamic acid in open heart surgery. 14578869 - A pilot study of therapeutic vaccination with envelope protein e1 in 35 patients with c... 19240379 - Adherence with long-term asthma management in patients who experienced hospitalized ast... 23357289 - Alterations in t-lymphocyte subpopulations in patients with complicated liver cirrhosis. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Lancet Volume: 341 ISSN: 0140-6736 ISO Abbreviation: Lancet Publication Date: 1993 May |
Date Detail:
|
Created Date: 1993-06-14 Completed Date: 1993-06-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 2985213R Medline TA: Lancet Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 1227-32 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Blood Cell Count Blood Loss, Surgical Blood Pressure Blood Transfusion / utilization* Double-Blind Method Drug Administration Schedule Erythropoietin / administration & dosage* Female Ferritins / blood Follow-Up Studies Hemoglobins / analysis Hip Prosthesis* Humans Injections, Subcutaneous Iron / administration & dosage, therapeutic use Male Middle Aged Postoperative Complications Recombinant Proteins / administration & dosage Thrombophlebitis / etiology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobins; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 7439-89-6/Iron; 9007-73-2/Ferritins |
| Comments/Corrections | |
Comment In:
|
Lancet. 1993 Jun 26;341(8861):1665
[PMID:
8100030
]
Lancet. 1993 Jun 26;341(8861):1665 [PMID: 8100031 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [A clinical study of pathophysiology and treatment of intractable gastric ulcers based on 24-hour in...
Next Document: Cerebral white matter lesions and atherosclerosis in the Rotterdam Study.